Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06507371 | Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer(mRCAT-III) | active not recruiting | Phase 3 | 170 | Sir Run Run Shaw HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02945566 | Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?(STAR-TREC) | active not recruiting | Phase 2 / Phase 3 | 380 | University of BirminghamOTHER |
| 5 |
| Jun 29, 2026 |
| clinicaltrials |
| NCT05557838 | Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC(TREMENDOUS) | active not recruiting | Phase 3 | 214 | AstraZenecaINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05144854 | A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | active not recruiting | Phase 3 | 626 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | Jun 25, 2026 | clinicaltrials |
| NCT06783140 | Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer(PLATINUM-CAN) | active not recruiting | Phase 2 / Phase 3 | 10 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02945033 | Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk(ASPIK French) | active not recruiting | Phase 3 | 264 | University Hospital, RouenOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06900543 | Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere(CHEERS) | active not recruiting | Phase 3 | 108 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT04513418 | Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy(POINT) | active not recruiting | Phase 3 | 244 | Hecheng Li M.D., Ph.DOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 302) | active not recruiting | Phase 3 | 500 | Revolution Medicines, Inc.INDUSTRY | 7 | Jun 2, 2026 | clinicaltrials |
| NCT04704934 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | active not recruiting | Phase 3 | 490 | Daiichi SankyoINDUSTRY | 24 | May 27, 2026 | clinicaltrials |
| NCT02572141 | FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)(OPTICAL) | active not recruiting | Phase 3 | 738 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04230187 | Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer(TRIBE-C) | active not recruiting | Phase 3 | 528 | Yanhong DengOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05239741 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | active not recruiting | Phase 3 | 100 | Merck Sharp & Dohme LLCINDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT04927780 | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer(PREOPANC-3) | active not recruiting | Phase 3 | 378 | Erasmus Medical CenterOTHER | 2 | May 15, 2026 | clinicaltrials |
| NCT05652894 | A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 190 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07241715 | Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)(CONVERGENCE) | active not recruiting | Phase 2 / Phase 3 | 300 | National University Hospital, SingaporeOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03017326 | Paediatric Hepatic International Tumour Trial(PHITT) | active not recruiting | Phase 3 | 450 | University of BirminghamOTHER | 14 | May 13, 2026 | clinicaltrials |
| NCT04550260 | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC(KUNLUN) | active not recruiting | Phase 3 | 640 | AstraZenecaINDUSTRY | 16 | May 13, 2026 | clinicaltrials |
| NCT01558921 | Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial(RAPIDO) | active not recruiting | Phase 3 | 920 | University Medical Center GroningenOTHER | 7 | May 1, 2026 | clinicaltrials |
| NCT01349881 | S0820, Adenoma and Second Primary Prevention Trial(PACES) | active not recruiting | Phase 3 | 354 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02758951 | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases(CAIRO6) | active not recruiting | Phase 2 / Phase 3 | 358 | Koen RoversOTHER | 2 | Mar 24, 2026 | clinicaltrials |
| NCT02647099 | Adjuvant Low Dose Aspirin in Colorectal Cancer(ALASCCA) | active not recruiting | Phase 3 | 626 | Anna MartlingOTHER | 4 | Mar 13, 2026 | clinicaltrials |
| NCT04094688 | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer(SOLARIS) | active not recruiting | Phase 3 | 455 | Alliance for Clinical Trials in OncologyOTHER | 2 | Mar 3, 2026 | clinicaltrials |
| NCT04928807 | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) | active not recruiting | Phase 3 | 231 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06356311 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)(TroFuse-015) | active not recruiting | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Feb 27, 2026 | clinicaltrials |
| NCT04428905 | Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | active not recruiting | Phase 3 | 403 | City of Hope Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05171660 | Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 446 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT01460589 | Early Commencement of Adjuvant Chemotherapy for Colon Cancer(ECTX) | active not recruiting | Phase 3 | 303 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03426904 | Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer | active not recruiting | Phase 3 | 708 | Kyungpook National University HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04854668 | A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 748 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04137107 | Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 220 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jan 26, 2026 | clinicaltrials |
| NCT05198609 | Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial | active not recruiting | Phase 3 | 214 | Sun Yat-sen UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06591520 | AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer | active not recruiting | Phase 3 | 682 | AkesoINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05904886 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)(SKYSCRAPER-14) | active not recruiting | Phase 3 | 687 | Hoffmann-La RocheINDUSTRY | 27 | Dec 31, 2025 | clinicaltrials |
| NCT04639180 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | active not recruiting | Phase 3 | 687 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07306663 | Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study(ESO-Nanjing7) | active not recruiting | Phase 3 | 242 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT04592913 | Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer | active not recruiting | Phase 3 | 957 | AstraZenecaINDUSTRY | 20 | Dec 24, 2025 | clinicaltrials |
| NCT03869892 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.(SOLSTICE) | active not recruiting | Phase 3 | 856 | Institut de Recherches Internationales ServierOTHER | 25 | Dec 22, 2025 | clinicaltrials |
| NCT05902533 | REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation(REDEL) | active not recruiting | Phase 2 / Phase 3 | 33 | University of CincinnatiOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy(COSMIC-312) | active not recruiting | Phase 3 | 837 | ExelixisINDUSTRY | 34 | Dec 11, 2025 | clinicaltrials |
| NCT05320692 | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | active not recruiting | Phase 3 | 423 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03829462 | Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients(NEXT-REGIRI) | active not recruiting | Phase 3 | 377 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05945901 | A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 669 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02505750 | Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma(OPERA) | active not recruiting | Phase 3 | 148 | Centre Antoine LacassagneOTHER | 3 | Sep 29, 2025 | clinicaltrials |
| NCT05980481 | A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer | active not recruiting | Phase 2 / Phase 3 | 201 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04669496 | Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | active not recruiting | Phase 2 / Phase 3 | 178 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05002127 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | active not recruiting | Phase 2 / Phase 3 | 127 | ALX Oncology Inc.INDUSTRY | 12 | Aug 7, 2025 | clinicaltrials |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases(ASAC) | active not recruiting | Phase 2 / Phase 3 | 466 | Oslo University HospitalOTHER | 3 | Jul 31, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 30, 2026source: clinicaltrials